Kornimate/medical-research-clean huggingface dataset:
snv1521 in participants with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this study is testing a new medicine, snv1521, for people with advanced cancers. the researchers want to find out if snv1521 is safe, well-tolerated, and effective in treating solid tumors. they are investigating different doses in order to find the most effective and safe one. they are also investigating whether it can be combined with other cancer therapies.


Eligibility criteria:
inclusion criteria: * advanced or metastatic solid tumor malignancy * evaluable or measurable disease (recist 1.1 criteria). * ecog performance status 0 or 1. * life expectancy \> 3 months exclusion criteria: * history of other malignancy within the past 2 years * prior diagnosis of myelodysplastic syndrome or acute myeloid leukemia * significant cardiovascular disease within 6 months * significant gastrointestinal disease * hiv infection with a cd4+ t-cell count \< 200 cells/μl and/or a detectable viral load * liver dysfunction
study evaluating the persistence, efficacy and tolerability of methotrexate in inflammatory bowel disease patients

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis

Summary: methotrexate is one of the immunosuppressants used in chronic inflammatory bowel disease (ibd). it is indicated as monotherapy for induction and maintenance treatment of crohn's disease (cd), or in combination with anti-tumor necrosis factor (tnf) agents for prevention of immunization. the main objective is to assess the persistence rate of methotrexate treatment in patients followed for chronic inflammatory bowel disease (ibd).

methotrexate is one of the immunosuppressants used in chronic inflammatory bowel disease (ibd). it is indicated as monotherapy for induction and maintenance treatment of crohn's disease (cd), or in combination with anti-tumor necrosis factor (tnf) agents for prevention of immunization thiopurines are the most commonly used immunosuppressants in ibd, which contrasts with rheumatology data where methotrexate is the first-line immunosuppressant. thiopurines and methotrexate have equivalent efficacy in cd 4. methotrexate is available in injectable (intramuscular (im) or subcutaneous (sc)) or tablet form. in ibd, only parenteral administration has been shown to be effective. there is no consensus on the optimal maintenance dosage. tolerance problems remain an obstacle to its use, even if the side effects are not severe. in this context, the objectives of this study are to describe the use of methotrexate in current practice in patients followed for ibd, its persistence, compliance, tolerance, as well as the factors associated with the persistence of treatment.

Eligibility criteria:
inclusion criteria: 1. person who has received full information on the organization of the research and has not objected to the use of this data 2. age ≥18 years 3. certain diagnosis of ibd (european crohn's colitis organization criteria) 4. introduction of methotrexate mono- or combination therapy between january 1, 2015 and december 31, 2022 5. minimum 6-month follow-up after initiation of methotrexate therapy 6. person affiliated with a social security plan or beneficiary of such a plan exclusion criteria: 1. age \<18 years 2. person referred to in articles l. 1121-5, l. 1121-7 and l1121-8 of the public health code * pregnant woman, parturient or nursing mother * minor (not emancipated) * adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * a person of full age who is unable to give consent 3. persons deprived of liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles l. 3212-1 and l. 3213-1
base hsp110 : a new therapeutic target and a new marker for prognosis of type msi colorectal cancer

Conditions: Rectum Cancer; Cancer of Colon

Summary: we collect prospectively and retrospectively, patients' demographic, pathological, surgical, therapeutic and prognosis informations in a database. after patient's consent to collect tumoural samples of their colorectal cancer after resection. we will then be able to evaluate the impact of hsp110, a chaperon protein, on their prognosis. other proteins (to be determined) will also be study, after.

to investigate the importance of hsp110de9 as a prognostic marker for colorectal cancer, we will analyze genotyping fluorescence quantitative rt-pcr and / or immunomarquage the presence of this mutant in a large cohort of patients (more than 2000 patients had or having a colorectal cancer). all patients have been or will be made in general and digestive surgery department at saint-antoine hospital. tumor fragments samples were or will be made on their tumor and keep it in the tumor bank of the saint-antoine hospital. all patients reported their no objection to the use of these tumor fragments for research purposes. a database will be built and correlated with the tumor fragments. this project is intended that the constitution of a clinical database including prognostic so that we make discoveries on hsp110de9 or other molecular biology to discover markers can be correlated with clinical data. in the absence of other studies on the subject, with no real knowledge of the prognostic impact of this mutant, we cannot provide an effective computation. we therefore propose to make a database of 2000 patients retrospectively and prospectively to obtain statistical results valid and powerful.

Eligibility criteria:
inclusion criteria: * all patients undergoing curative colorectal cancer in general and digestive surgery department at saint-antoine hospital. * patients reporting their non-opposition to the use of tissue samples taken from their specimen for research purposes. exclusion criteria: * patients who did not report their non-opposition to the use of tissue samples taken from their specimen for research purposes.
laboratory and clinical data in antiphospholipid patients

Conditions: Antiphospholipid Syndrome

Summary: to constitute a registry of antiphospholipid antibodies positive-patients

an international web-based application, the redcap (research electronic data capture), captures data on patient demographics, apl-related clinical and laboratory characteristics, and medications. the inclusion criteria are: a) age between 18 and 60 years; and b) persistent (at least 12 weeks apart) apl-positivity within 12 months prior to screening; positivity is defined as anticardiolipin antibodies (acl) igg/m/a (\> 40 gpl/mpl/apl, medium-to-high titer, and/or greater than the 99th percentile), anti-β2-glycoprotein-i (aβ2gpi) igg/m/a (\> 40 units, medium-to-high titer), positive lupus anticoagulant (la) test based on international society on thrombosis and hemostasis and other current guidelines. patients are followed every 12 ± 3 months with clinical data and blood collection. blood drawn is done at inclusion and every year.

Eligibility criteria:
inclusion criteria: * age between 18 and 60 years; * persistent (at least 12 weeks apart) apl-positivity within 12 months prior to screening exclusion criteria: * no inform consent * impossible follow up * pregnancy

Keywords: antiphospholipid antibodies
effects of pallidal deep brain stimulation location on motor impairment in parkinson's disease

Conditions: Parkinson's Disease

Summary: this protocol will characterize the effects of deep brain stimulation (dbs) location (both adverse and beneficial) on motor signs in people with parkinson's disease (pd). this information can be used to inform future dbs protocols to tailor stimulation to the specific needs of a patient. if targeted dorsal gp stimulation is shown to significantly improve motor features that are typically resistant to dopamine replacement therapy, these experiments will likely have major impact on clinical practice by providing a potential strategy to these medically intractable symptoms.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd * have undergone neurosurgery to implant deep brain stimulators in the globus pallidus (gp dbs) or subthalamic nucleus (stn) * existing 7t brain imagery exclusion criteria: * history of musculoskeletal disorders that significantly affect movement of the upper or lower limbs * other significant neurological disorder * history of dementia or cognitive impairment as found with ubacc (or maccat-cr) * post-operative complications or adverse effects
inflammatory response in schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia affects a significant proportion of the population and current levels of understanding of the illness is inadequate to treat it effectively. converging lines of evidence suggest that neuroinflammation occurs in schizophrenia, and specifically over-activity of brain-resident immune cells called microglia. it is however unclear whether activated microglia play a primary role in schizophrenia, or whether this is a secondary phenomenon of no pathophysiological significance. the investigators therefore plan to test the effect of a monoclonal antibody (natalizumab) on psychotic symptoms in a cohort of first episode psychosis patients.

one of the key aims of the study is to determine if there is a relationship between change in imaging inflammation markers from baseline to follow-up and changes in other markers of inflammation over the same period. in september 2021, an open label arm for natalizumab was added to the study. the relationship between changes in imaging inflammation markers and changes in other markers of inflammation will be analysed within subjects including all patients who received natalizumab.

Eligibility criteria:
inclusion criteria: 1. aged 18-50 years 2. diagnosis of schizophrenia or other psychotic disorder (diagnostic and statistical manual of mental disorders-5 (dsm-5); 3. symptomatic, defined as one or more positive symptom \>3 and one or more negative symptom \>3 on the positive and negative syndrome scale (panss); 4. no acute relapse and psychiatrically stable for \>1 month before screening; exclusion criteria: 1. history of significant co-morbid cns disorder (including significant head trauma or significant loss of consciousness, parkinson's disease, epilepsy, alzheimer's dementia, huntington's disease). 2. any absolute contraindications to natalizumab, as per natalizumab spc 3. current or recent (last 3 months) infection, or history of significant infection, or an immunocompromised state 4. previous use of natalizumab or previous use of other monoclonal antibody. 5. ongoing long-standing use of oral steroids or non-steroidal anti-inflammatory drugs. 6. pregnancy and/or breast-feeding. 7. substance dependence/abuse other than to cigarettes.
registry of sustained immunity to covid-19 among eskd patients

Conditions: SARS-CoV-2 Infection; Anti-SARS-CoV-2 Infection

Summary: this is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a davita center. the objective of this study is to understand whether and to what degree anti-sars-cov-2 antibodies mitigate the risk of subsequent sars-cov-2 infection and covid disease within the eskd population.

this is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a davita center. the objective of this study is to understand whether and to what degree anti-sars-cov-2 antibodies mitigate the risk of subsequent sars-cov-2 infection and covid disease within the eskd population. following informed consent, participants will undergo baseline serologic characterization for anti-sars-cov-2 igm and igg. the study is planned to align with the present wave of covid-19. enrollment will continue until the total sample size of 2500 is reached or until the study sponsor determines. should there be a subsequent wave of covid- 19, participants will be actively surveiled for evidence of sars-cov-2 infection and for covid-19 disease. the relationship between baseline serologic status and subsequent infection/disease will be determined. this study will have 2 distinct phases. phase 1 (baseline characterization) start will be triggered by the sponsor and may start at different times at the active sites. participants will be consented and enrolled and blood will be collected for anti-sars-cov-2 antibodies. phase 2: start will be triggered by the sponsor in the fall of 2020 and each geographic study location may be triggered to start at separate times. study participants will be followed prospectively for incidence and severity of covid-19. study visits will commence upon sponsor trigger and will occur once monthly for 4 months.

Eligibility criteria:
inclusion criteria: * between ≥18 and 80 years of age, inclusive. * ability to provide informed consent. * currently receiving hemodialysis treatment for end-stage kidney disease at a davita dialysis center. exclusion criteria: -

Keywords: immunoglobulin g immunoglobulin m
comparison of the effects of vecuronium and cisatracurium on electrophysiologic monitoring during neurosurgery

Conditions: Motor Evoked Potential Monitoring; General Anesthesia; Neurosurgery; Brain Tumor; Spine Tumor; Cerebral Aneurysm

Summary: recently intraoperative motor evoked potential monitoring (mep) is widely used to reduce neural damage during neurosurgery. as neuromuscular blockade(nmb) during mep monitoring decreases the amplitude of mep, partial nmb is usually maintained during general anesthesia. continuous infusion of nmb agent is preferred than bolus infusion during mep monitoring. there are a lot of nmb agents in clinical use. but there have been no reports about the effect of changing nmb agent on efficacy of mep monitoring. therefore, the investigators performed a randomized controlled trial to evaluate the effect of changing nmb agent on the variability of mep amplitude during neurosurgery.

recently intraoperative motor evoked potential monitoring (mep) is widely used to reduce neural damage during neurosurgery. as neuromuscular blockade(nmb) during mep monitoring decreases the amplitude of mep, partial nmb is usually maintained during general anesthesia. continuous infusion of nmb agent is preferred than bolus infusion during mep monitoring. there are a lot of nmb agents in clinical use. but there have been no reports about the effect of changing nmb agent on efficacy of mep monitoring. therefore, the investigators performed a randomized controlled trial to evaluate the effect of changing nmb agent on the variability of mep amplitude during neurosurgery.

Eligibility criteria:
inclusion criteria: * adult patients undergoing neurosurgery with intraoperative motor evoked potential monitoring exclusion criteria: * patients who can not undergo motor evoked potential monitoring due to central or peripheral neuromuscular disease (e.g. cerebral palsy, myasthenia gravis, acute spinal injury, neurologic shock) * patients with hepatic or renal disease with altered metabolism of vecuronium * patients with medication which influence the metabolism of vecuronium (e.g. calcium channel blocker, aminoglycoside antibiotics, lithium, mgso4)

Keywords: motor evoked potential monitoring general anesthesia neurosurgery cisatracurium vecuronium
the effect of retatrutide once weekly on cardiovascular outcomes and kidney outcomes in adults living with obesity (triumph-outcomes)

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

Summary: the main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. the trial will enroll adults with body mass index 27 kg/m\^2 or higher and atherosclerotic cardiovascular disease and/or chronic kidney disease. the study will last for about 5 years. participants will have up to 27 clinic visits with the study doctor.


Eligibility criteria:
inclusion criteria: * participants may be without type 2 diabetes (t2d), or with t2d if their hemoglobin a1c (hba1c) is 10% or lower * participants have established atherosclerotic cardiovascular disease (ascvd) and/or chronic kidney disease (ckd), as evidenced at least one of the following: * coronary artery disease * cerebrovascular disease * peripheral arterial disease * chronic kidney disease defined as: * egfr \ 30 milligram/gram (mg/g) (0.030 mg/mg) * egfr \ 100 mg/g (0.100 mg/mg), or * egfr \ 300 mg/g (0.300 mg/mg) (egfr is calculated by central lab based on chronic kidney disease epidemiology collaboration (ckd-epi) creatinine-cystatin c equation as determined by central lab) * a body mass index of ≥27.0 kilograms per meter squared (kg/m\^2) exclusion criteria: diabetes related: * participants have type 1 diabetes or any history of diabetic ketoacidosis cv related: * participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization: * myocardial infarction * acute coronary syndrome * stroke, or * coronary, peripheral, or carotid artery arterial revascularization procedure. * have acute decompensated heart failure requiring hospitalization. * have new york heart association (nyha) classification class iv heart failure at screening kidney related: * participants have an egfr \<20 ml/min/1.73 m\^2 at screening * have uacr \>5000 mg/g (5.000 mg/mg) at screening * have received any form of dialysis ≤ 90 days from the date of randomization * have either undergone a kidney transplant or have a transplant procedure scheduled other medical conditions: * participants have had or plan to have a surgical treatment for obesity, * have a history of chronic or acute pancreatitis * have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (men) syndrome type 2 * have a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction

Keywords: cardiovascular disease kidney disease major adverse cardiovascular events (mace) renal outcomes cardiovascular risk reduction kidney disease progression cardiometabolic risk factors cardiovascular outcomes kidney outcomes type 2 diabetes heart disease coronary artery disease cerebrovascular disease peripheral arterial disease nonfatal myocardial infarction (mi) nonfatal stroke cardiovascular (cv) death hospitalization or urgent visit due to heart failure (hf) renal death end stage kidney disease (eskd)
risedronate therapy in the treatment of low bone mineral density in crohn's disease

Conditions: Crohn's Disease; Low Bone Mineral Density

Summary: the occurrence of bone loss in crohn's disease patients is an important clinical problem for both patients with and without active disease. while therapy does exist for treatment and prevention of low bmd, evidence of its efficacy in crohn's disease patients is lacking. the current standard of therapy in canada for the treatment of osteoporosis is etidronate, with adequate calcium and vitamin d supplementation. the primary objective of the study is to assess the efficacy of risedronate, compared to placebo, administered once-weekly, in the treatment of low bmd of the spine and hip in patients with crohn's disease at 12 months, based on an intention-to-treat analysis.


Eligibility criteria:
inclusion criteria: * subjects who are 18 years of age, or older. * crohn's disease, as documented by clinical, radiologic, endoscopic or histologic examination. * osteoporosis (t score less than -2.5) or osteopenia (t score between -1.0 and -2.5), as determined by dual energy x-ray absorptiometry. exclusion criteria: * known bone disorders other than osteoporosis (such as hyperparathyroidism, paget's disease, renal osteodystrophy and documented osteomalacia) * abnormal thyroid function. those patients on thyroxine replacement must not have had a change in dose in the two months prior to prospective data collection program entry * clinically significant renal impairment (serum creatinine ≥ 2x normal). * clinical short bowel syndrome * patients on total parenteral or enteral nutrition * spinal anatomy that would not allow adequate assessment of lateral spine using dexa * patients who had received: 1. previous bisphosphonate therapy 2. fluoride supplement in the 24 months prior to entry 3. calcium supplements of more than 1.0g/day in the 6 months prior to entry 4. vitamin d supplements greater than 1000 iu/day in the 6 months prior to entry 5. calcitonin in the 3 months prior to entry * females on hormone replacement therapy who do not agree to continue the therapy for the duration of the prospective data collection program * men on testosterone who do not agree to continue it for the duration of the prospective data collection program * pregnancy or women who are breastfeeding

Keywords: crohn's disease low bone mineral density inflammatory bowel disease bisphosphonate
coping with covid-19( cwc-19)

Conditions: COVID-19

Summary: the purpose of this study is 1) to understand effects of covid-19 crisis on wellness of pulmonary and critical care faculty and trainees who are at frontline fighting this pandemic 2) assess the effectiveness of series of weekly web based crisis management coaching from world renowned experts in coaching and 3) identify future areas of opportunities in physician wellness


Eligibility criteria:
inclusion criteria: * any faculty, staff, or trainee from duke pulmonary and critical care that consents to being in the study exclusion criteria: -
magnet for corneal foreign bodies

Conditions: Corneal Foreign Body

Summary: this is a prospective, interventional study to assess the effectiveness and safety of a commercially available "eye magnet" to remove corneal foreign bodies.

the vast majority of corneal foreign bodies are metallic and thus are frequently ferromagnetic. consequently, it may be possible to use a magnet to remove most corneal foreign bodies. there are commercially available products for removing corneal foreign bodies, but there are no published studies assessing these devices. this will be a prospective interventional study to assess the use of an eye magnet for the removal of metallic corneal foreign bodies in the emergency department. after the patient signs written, informed consent, the physician will attempt to remove the corneal foreign body with the north by honeywell 326734g eye magnet with loop. if the physician is unable to remove the corneal foreign body with the magnet, he or she may proceed with standard care. the treating physician will fill out a brief data collection form for each patient to track various outcomes as discussed below.

Eligibility criteria:
inclusion criteria: * present to the emergency department with a metallic corneal foreign body exclusion criteria: * prisoners * pregnant women * have pacemakers or metallic facial implants * possible globe rupture
assessment of niacinamide cosmetic product efficacy in model of irritant contact dermatitis

Conditions: Contact Dermatitis

Summary: testing the effectiveness and safety of cosmetics with niacinamide in irritant contact dermatitis: a randomised, controlled trial will be conducted at ussm. healthy volunteers will be included (at least 25) and test sites are forearms. sodium lauryl sulphate will be used to induce contact dermatitis and participants will be measured for 7 days

the efficacy of niacinamide cosmetic product on contact dermatitis will be evaluated using courage khazaka device and probes for hydration, redness and transepidermal water loss

Eligibility criteria:
inclusion criteria: * young, healthy volunteers who gave written informed consent exclusion criteria: * skin disease, skin damage on measurement sites, use of corticosteroids and immunomodulators a month prior to the inclusion and during the trial, non-adherence to the trial protocol, exposure to artificial uv radiation, pregnancy and lactation